Open Access

Sinensetin suppresses angiogenesis in liver cancer by targeting the VEGF/VEGFR2/AKT signaling pathway

  • Authors:
    • Xiaο Li
    • Yan Li
    • Yuan Wang
    • Fuhong Liu
    • Yanjun Liu
    • Jiangjiu Liang
    • Rucai Zhan
    • Yue Wu
    • He Ren
    • Xiuyuan Zhang
    • Ju Liu
  • View Affiliations

  • Published online on: March 31, 2022     https://doi.org/10.3892/etm.2022.11287
  • Article Number: 360
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sinensetin (SIN) is a polymethoxy flavone primarily present in citrus fruits. This compound has demonstrated anticancer activity. However, the underlying mechanism of its action has not been fully understood. The present study investigated the impact of SIN on angiogenesis in a liver cancer model. In a murine xenograft tumor model, SIN inhibited the growth of HepG2/C3A human liver hepatoma cell‑derived tumors and reduced the expression levels of platelet/endothelial cell adhesion molecule‑1 and VEGF. In HepG2/C3A cells, SIN repressed VEGF expression by downregulating hypoxia‑inducible factor expression. In cultured human umbilical vein endothelial cells, SIN increased apoptosis and repressed migration and tube formation. In addition, SIN decreased the phosphorylation of VEGFR2 and inhibited the AKT signaling pathway. Molecular docking demonstrated that the VEGFR2 core domain effectively combined with SIN at various important residues. Collectively, these data suggested that SIN inhibited liver cancer angiogenesis by regulating VEGF/VEGFR2/AKT signaling.
View Figures
View References

Related Articles

Journal Cover

May-2022
Volume 23 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li X, Li Y, Wang Y, Liu F, Liu Y, Liang J, Zhan R, Wu Y, Ren H, Zhang X, Zhang X, et al: Sinensetin suppresses angiogenesis in liver cancer by targeting the VEGF/VEGFR2/AKT signaling pathway. Exp Ther Med 23: 360, 2022
APA
Li, X., Li, Y., Wang, Y., Liu, F., Liu, Y., Liang, J. ... Liu, J. (2022). Sinensetin suppresses angiogenesis in liver cancer by targeting the VEGF/VEGFR2/AKT signaling pathway. Experimental and Therapeutic Medicine, 23, 360. https://doi.org/10.3892/etm.2022.11287
MLA
Li, X., Li, Y., Wang, Y., Liu, F., Liu, Y., Liang, J., Zhan, R., Wu, Y., Ren, H., Zhang, X., Liu, J."Sinensetin suppresses angiogenesis in liver cancer by targeting the VEGF/VEGFR2/AKT signaling pathway". Experimental and Therapeutic Medicine 23.5 (2022): 360.
Chicago
Li, X., Li, Y., Wang, Y., Liu, F., Liu, Y., Liang, J., Zhan, R., Wu, Y., Ren, H., Zhang, X., Liu, J."Sinensetin suppresses angiogenesis in liver cancer by targeting the VEGF/VEGFR2/AKT signaling pathway". Experimental and Therapeutic Medicine 23, no. 5 (2022): 360. https://doi.org/10.3892/etm.2022.11287